PanR1, a dominant negative missense allele of the gene encoding TNF-α (Tnf), does not impair lymphoid development

Journal of Immunology

Volumn 176, Issue 12, 2006, Pages 7525-7532

  Rutschmann, Sophie ^a   Hoebe, Kasper ^a   Zalevsky, Jonathan ^b   Du, Xin ^a   Mann, Navjiwan ^a   Dahiyat, Bassil I ^b   Steed, Paul ^b   Beutler, Bruce ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Xencor Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; AMINO ACID; CYTOSINE; PROLINE; THREONINE; TUMOR NECROSIS FACTOR ALPHA;

ALLELE; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE MODEL; DISEASE PREDISPOSITION; FEMALE; GENE; HOMOZYGOTE; IMMUNOREACTIVITY; INNATE IMMUNITY; LISTERIA MONOCYTOGENES; LISTERIOSIS; LYMPHOID TISSUE; MACROPHAGE; MALE; MISSENSE MUTATION; MOUSE; MOUSE MUTANT; NONHUMAN; PANR1 GENE; PEYER PATCH; PHENOTYPE; PRIORITY JOURNAL; SPLEEN; TNF GENE;

EID: 33744924870     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.12.7525     Document Type: Article

References (56)

1. Beutler, B., I. W. Milsark, and A. C. Cerami. 1985. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229: 869-871.
2. Beutler, B., and A. Cerami. 1989. The biology of cachectin/TNF: a primary mediator of the host response. Annu. Rev. Immunol. 7: 625-655.
3. Chen, G., and D. V. Goeddel. 2002. TNF-R1 signaling: a beautiful pathway. Science 296: 1634-1635.
4. Hehlgans, T., and K. Pfeffer. 2005. The intriguing biology of the tumor necrosis factor/tumor necrosis factor receptor superfamily: players, rules and the games. Immunology 115: 1-20.
5. Locksley, R. M., N. Killeen, and M. J. Lenardo. 2001. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104: 487-501.
6. Garcia, I., Y. Miyazaki, K. Araki, M. Araki, R. Lucas, G. E. Grau, G. Milon, Y. Belkaid, C. Montixi, W. Lesslauer, et al. 1995. Transgenic mice expressing high levels of soluble TNF-R1 fusion protein are protected from lethal septic shock and cerebral malaria, and are highly sensitive to Listeria monocytogenes and Leishmania major infections. Eur. J. Immunol. 25: 2401-2407.
7. Havell, E. A. 1987. Production of tumor necrosis factor during murine listeriosis. J. Immunol. 139: 4225-4231.
8. Havell, E. A. 1989. Evidence that tumor necrosis factor has an important role in antibacterial resistance. J. Immunol. 143: 2894-2899.
9. Pasparakis, M., L. Alexopoulou, V. Episkopou, and G. Kollias. 1996. Immune and inflammatory responses in TNF α-deficient mice: a critical requirement for TNF α in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J. Exp. Med. 184: 1397-1411.
10. Pfeffer, K., T. Matsuyama, T. M. Kundig, A. Wakeham, K. Kishihara, A. Shahinian, K. Wiegmann, P. S. Ohashi, M. Kronke, and T. W. Mak. 1993. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73: 457-467.
11. Plitz, T., U. Huffstadt, R. Endres, E. Schaller, T. W. Mak, H. Wagner, and K. Pfeffer. 1999. The resistance against Listeria monocytogenes and the formation of germinal centers depend on a functional death domain of the 55 kDa tumor necrosis factor receptor. Eur. J. Immunol. 29: 581-591.
12. Rothe, J., W. Lesslauer, H. Lotscher, Y. Lang, P. Koebel, F. Kontgen, A. Althage, R. Zinkernagel, M. Steinmetz, and H. Bluethmann. 1993. Mice lacking the tumor necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364: 798-802.
13. Kindler, V., A. P. Sappino, G. E. Grau, P. F. Piguet, and P. Vassalli. 1989. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56: 731-740.
14. Feldmann, M. 2002. Development of anti-TNF therapy for rheumatoid arthritis. Nat. Rev. Immunol. 2: 364-371.
15. Feldmann, M., and R. N. Maini. 2001. Anti-TNF α therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. 19: 163-196.
16. Sands, B. E. 2004. Why do anti-tumor necrosis factor antibodies work in Crohn's disease? Rev. Gastroenterol. Disord. 4 (Suppl. 3): S10-17.
17. Mak, T. W., and W. C. Yeh. 2002. Signaling for survival and apoptosis in the immune system. Arthritis Res. 4 (Suppl. 3): S243-252.
18. Galon, J., I. Aksentijevich, M. F. McDermott, J. J. O'Shea, and D. L. Kastner. 2000. TNFRSF1A mutations and autoinflammatory syndromes. Curr. Opin. Immunol. 12: 479-486.
19. Black, R. A., C. T. Rauch, C. J. Kozlosky, J. J. Peschon, J. L. Slack, M. F. Wolfson, B. J. Castner, K. L. Stocking, P. Reddy, S. Srinivasan, et al. 1997. A metalloproteinase disintegrin that releases tumor-necrosis factor-α from cells. Nature 385: 729-733.
20. Moss, M. L., S. L. Jin, M. E. Milla, D. M. Bickett, W. Burkhart, H. L. Carter, W. J. Chen, W. C. Clay, J. R. Didsbury, D. Hassler, et al. 1997. Cloning of a disintegrin metalloproteinase that processes precursor tumor-necrosis factor-α. Nature 385: 733-736.
21. Kriegler, M., C. Perez, K. DeFay, I. Albert, and S. D. Lu. 1988. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 53: 45-53.
22. Ruuls, S. R., R. M. Hoek, V. N. Ngo, T. McNeil, L. A. Lucian, M. J. Janatpour, H. Korner, H. Scheerens, E. M. Hessel, J. G. Cyster, et al. 2001. Membrane-bound TNF supports secondary lymphoid organ structure but is subservient to secreted TNF in driving autoimmune inflammation. Immunity 15: 533-543.
23. Canault, M., F. Peiretti, C. Mueller, F. Kopp, P. Morange, S. Rihs, H. Portugal, I. Juhan-Vague, and G. Nalbone. 2004. Exclusive expression of transmembrane TNF-α in mice reduces the inflammatory response in early lipid lesions of aortic sinus. Atherosclerosis 172: 211-218.
24. Mueller, C., N. Corazza, S. Trachsel-Loseth, H. P. Eugster, M. Buhler-Jungo, T. Brunner, and M. A. Imboden. 1999. Noncleavable transmembrane mouse tumor necrosis factor-α (TNFα) mediates effects distinct from those of wild-type TNFα in vitro and in vivo. J. Biol. Chem. 274: 38112-38118.
25. Olleros, M. L., R. Guler, N. Corazza, D. Vesin, H. P. Eugster, G. Marchal, P. Chavarot, C. Mueller, and I. Garcia. 2002. Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guerin infection in the absence of secreted TNF and lymphotoxin-α. J. Immunol. 168: 3394-3401.
26. Fu, Y. X., and D. D. Chaplin. 1999. Development and maturation of secondary lymphoid tissues. Annu. Rev. Immunol. 17: 399-433.
27. Mebius, R. E. 2003. Organogenesis of lymphoid tissues. Nat. Rev. Immunol. 3: 292-303.
28. Korner, H., M. Cook, D. S. Riminton, F. A. Lemckert, R. M. Hoek, B. Ledermann, F. Kontgen, B. Fazekas de St Groth, and J. D. Sedgwick. 1997. Distinct roles for lymphotoxin-α and tumor necrosis factor in organogenesis and spatial organization of lymphoid tissue. Eur. J. Immunol. 27: 2600-2609.
29. Kuprash, D. V., A. V. Tumanov, D. J. Liepinsh, E. P. Koroleva, M. S. Drutskaya, A. A. Kruglov, A. N. Shakhov, E. Southon, W. J. Murphy, L. Tessarollo, et al. 2005. Novel tumor necrosis factor-knockout mice that lack Peyer's patches. Eur. J. Immunol. 35: 1592-1600.
30. Marino, M. W., A. Dunn, D. Grail, M. Inglese, Y. Noguchi, E. Richards, A. Jungbluth, H. Wada, M. Moore, B. Williamson, et al. 1997. Characterization of tumor necrosis factor-deficient mice. Proc. Natl. Acad. Sci. USA 94: 8093-8098.
31. Pasparakis, M., L. Alexopoulou, M. Grell, K. Pfizenmaier, H. Bluethmann, and G. Kollias. 1997. Peyer's patch organogenesis is intact yet formation of B lymphocyte follicles is defective in peripheral lymphoid organs of mice deficient for tumor necrosis factor and its 55-kDa receptor. Proc. Natl. Acad. Sci. USA 94: 6319-6323.
32. Le Hir, M., H. Bluethmann, M. H. Kosco-Vilbois, M. Muller, F. di Padova, M. Moore, B. Ryffel, and H. P. Eugster. 1996. Differentiation of follicular dendritic cells and full antibody responses require tumor necrosis factor receptor-1 signaling. J. Exp. Med. 183: 2367-2372.
33. Neumann, B., A. Luz, K. Pfeffer, and B. Holzmann. 1996. Defective Peyer's patch organogenesis in mice lacking the 55-kD receptor for tumor necrosis factor. J. Exp. Med. 184: 259-264.
34. Tumanov, A. V., D. V. Kuprash, and S. A. Nedospasov. 2003. The role of lymphotoxin in development and maintenance of secondary lymphoid tissues. Cytokine Growth Factor Rev. 14: 275-288.
35. Garrelds, I. M., F. J. Zijlstra, C. J. Tak, I. L. Bonta, I. Beckmann, and S. Ben-Efraim. 1993. A comparison between two methods for measuring tumor necrosis factor in biological fluids. Agents Actions 38 Spec No: C89-91.
36. Portnoy, D. A., P. S. Jacks, and D. J. Hinrichs. 1988. Role of hemolysin for the intracellular growth of Listeria monocytogenes. J. Exp. Med. 167: 1459-1471.
37. Steed, P. M., M. G. Tansey, J. Zalevsky, E. A. Zhukovsky, J. R. Desjarlais, D. E. Szymkowski, C. Abbott, D. Carmichael, C. Chan, L. Cherry, et al. 2003. Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science 301: 1895-1898.
38. Browning, J. L., I. D. Sizing, P. Lawton, P. R. Bourdon, P. D. Rennert, G. R. Majeau, C. M. Ambrose, C. Hession, K. Miatkowski, D. A. Griffiths, et al. 1997. Characterization of lymphotoxin-α β complexes on the surface of mouse lymphocytes. J. Immunol. 159: 3288-3298.
39. Mackay, F., P. R. Bourdon, D. A. Griffiths, P. Lawton, M. Zafari, I. D. Sizing, K. Miatkowski, A. Ngam-ek, C. D. Benjamin, C. Hession, et al. 1997. Cytotoxic activities of recombinant soluble murine lymphotoxin-α and lymphotoxin-α β complexes. J. Immunol. 159: 3299-3310.
40. Pahl, H. L. 1999. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18: 6853-6866.
41. Baeyens, K. J., H. L. De Bondt, A. Raeymaekers, W. Fiers, and C. J. De Ranter. 1999. The structure of mouse tumor-necrosis factor at 1.4 A resolution: towards modulation of its selectivity and trimerization. Acta Crystallogr. D Biol. Crystallogr. 55: 772-778.
42. Banner, D. W., A. D'Arcy, W. Janes, R. Gentz, H. J. Schoenfeld, C. Broger, H. Loetscher, and W. Lesslauer. 1993. Crystal structure of the soluble human 55 kd TNF receptor-human TNF β complex: implications for TNF receptor activation. Cell 73: 431-445.
43. Yamagishi, J., H. Kawashima, N. Matsuo, M. Ohue, M. Yamayoshi, T. Fukui, H. Kotani, R. Furuta, K. Nakano, and M. Yamada. 1990. Mutational analysis of structure-activity relationships in human tumor necrosis factor-α. Protein Eng. 3: 713-719.
44. Eck, M. J., and S. R. Sprang. 1989. The structure of tumor necrosis factor-α at 2.6 A resolution: implications for receptor binding. J. Biol. Chem. 264: 17595-17605.
45. Jones, E. Y., D. I. Stuart, and N. P. Walker. 1989. Structure of tumor necrosis factor. Nature 338: 225-228.
46. Sprang, S. R., and M. J. Eck. 1992. The 3-D structure of TNF. In Tumor Necrosis Factor: The Molecules and Their Emerging Role in Medicine. B. Beutler, ed. Raven, New York, pp. 11-32.
47. Eck, M. J., M. Ultsch, E. Rinderknecht, A. M. de Vos, and S. R. Sprang. 1992. The structure of human lymphotoxin (tumor necrosis factor-β) at 1.9-A resolution. J. Biol. Chem. 267: 2119-2122.
48. Flynn, J. L., M. M. Goldstein, J. Chan, K. J. Triebold, K. Pfeffer, C. J. Lowenstein, R. Schreiber, T. W. Mak, and B. R. Bloom. 1995. Tumor necrosis factor-α is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2: 561-572.
49. Peschon, J. J., D. S. Torrance, K. L. Stocking, M. B. Glaccum, C. Otten, C. R. Willis, K. Charrier, P. J. Morrissey, C. B. Ware, and K. M. Mohler. 1998. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J. Immunol. 160: 943-952.
50. Kolls, J., K. Peppel, M. Silva, and B. Beutler. 1994. Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer. Proc. Natl. Acad. Sci. USA 91: 215-219.
51. Cheers, C., and I. F. McKenzie. 1978. Resistance and susceptibility of mice to bacterial infection: genetics of listeriosis. Infect. Immun. 19: 755-762.
52. Roach, D. R., H. Briscoe, B. M. Saunders, and W. J. Britton. 2005. Independent protective effects for tumor necrosis factor and lymphotoxin α in the host response to Listeria monocytogenes infection. Infect. Immun. 73: 4787-4792.
53. Van Ostade, X., J. Tavernier, T. Prange, and W. Fiers. 1991. Localization of the active site of human tumor necrosis factor (hTNF) by mutational analysis. EMBO J. 10: 827-836.
54. Van Ostade, X., P. Vandenabeele, J. Tavernier, and W. Fiers. 1994. Human tumor necrosis factor mutants with preferential binding to and activity on either the R55 or R75 receptor. Eur. J. Biochem. 220: 771-779.
55. Zhang, X. M., I. Weber, and M. J. Chen. 1992. Site-directed mutational analysis of human tumor necrosis factor-α receptor binding site and structure-functional relationship. J. Biol. Chem. 267: 24069-24075.
56. Peppel, K., D. Crawford, and B. Beutler. 1991. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J. Exp. Med. 174: 1483-1489.